News

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...
Pharmabiz

AstraZeneca’s RESOLUTE phase III trial of Fasenra to treat chronic obstructive pulmonary disease fails to meet primary endpoint

AstraZeneca’s RESOLUTE phase III trial of Fasenra to treat chronic obstructive pulmonary disease fails to meet primary endpoint: Cambridge, UK Thursday, September 18, 2025, 15:0 ...

Digital cell twin opens up new avenues in lung cancer research

A team led by Christian Baumgartner of the Institute of Health Care Engineering at Graz University of Technology (TU Graz) ...

Basal stem-like cells identified as origin of small cell lung cancer in lab models

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
The Lancet

Physical activity and polluted air: implications for COPD prevention and policy

Regular physical activity reduces the risk of chronic obstructive pulmonary disease (COPD)1 and improves the prognosis in affected patients.2 In contrast, ambient air pollution, is a substantial risk ...